"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 3 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 3 | 1 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 4 | 2 | 6 |
| 2018 | 7 | 2 | 9 |
| 2019 | 6 | 2 | 8 |
| 2020 | 11 | 5 | 16 |
| 2021 | 11 | 6 | 17 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 0 | 9 |
| 2024 | 8 | 7 | 15 |
| 2025 | 14 | 3 | 17 |
| 2026 | 6 | 1 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Enhancing uptake of PrEP for her via organizational research and individual actions (EUPHORIA): Protocol for a stepped-wedge cluster randomized trial. PLoS One. 2026; 21(8):e0355623.
-
Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. Adv Ther. 2026 Aug; 43(8):3535-3551.
-
The safety and tolerability of oral TDF/FTC as pre-exposure prophylaxis among men who have sex with men in China: a prospective cohort study. BMC Infect Dis. 2026 May 21; 26(1).
-
Brief Report: Long-Acting Injectable PrEP Can Substantially Reduce HIV Incidence in Los Angeles County: A Simulation Study. J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):273-278.
-
Daily PrEP and event-driven PrEP adherence for men who have sex with men in China. Sex Health. 2026 02 05; 23(1).
-
Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States. J Int AIDS Soc. 2026 Feb; 29(2):e70082.
-
A cross-sectional survey to explore healthcare providers' experiences and attitudes toward HIV pre-exposure prophylaxis for women in family planning centers of Greater Paris. PLoS One. 2026; 21(1):e0337510.
-
Barriers to Adolescent Pre-exposure prophylaxis and Sexual Health Care in Pediatric Versus Family Medicine Providers. AIDS Patient Care STDS. 2025 12; 39(12):515-524.
-
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. J Antimicrob Chemother. 2025 11 04; 80(11):3092-3100.
-
Barriers to Same-Day Pre-exposure Prophylaxis (PrEP) Implementation in Federally Funded HIV Clinics Within High-Burden Areas of the U.S.: A Coincidence Analysis. AIDS Behav. 2026 Feb; 30(2):558-570.